H.R. 4619 · 116th Congress
Pharmaceutical Rebates for Excessive Pricing Above Inflation Act
- Stage
- In committee
- Sponsor
- Jan Schakowsky
- Introduced
- 2019-10-08
- Latest action
- 2019-10-09 · Referred to the Subcommittee on Health.
Summary
Pharmaceutical Rebates for Excessive Pricing Above Inflation Act or the Pharmaceutical REPAI Act
This bill requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under the Medicare prescription drug benefit that cost $100 or more and for which the average manufacturer price increases faster than inflation.